Exploring the consequences of greater price transparency on the dynamics of pharmaceutical
markets
For some time, governments, stakeholders and civil society have been voicing the need
for greater transparency in pharmaceutical pricing. The 2018 OECD report Pharmaceutical
Innovation and Access to Medicines suggested that increased price transparency could
promote public accountability, while potentially delivering efficiencies to health
systems by including economic considerations in coverage, treatment decisions and
budget allocation. Despite this, precisely what should be made more transparent, and
how greater transparency would affect the functioning of markets, have been poorly
characterised. To help frame the policy debate, the OECD undertook an exploration
of the potential consequences of greater price transparency on market dynamics. The
work included a roundtable and a series of semi-structured interviews, with participation
by 19 experts in pharmaceutical pricing, economics of pharmaceutical markets, competition,
and law. With an extensive review of the current practice and relevant literature
as a preface, this report presents the key findings from those consultations.
Published on September 08, 2022
In series:OECD Health Working Papersview more titles